BEAM vs. GRFS, TLX, TGTX, NUVL, LEGN, LNTH, AXSM, ADMA, PCVX, and MRUS
Should you be buying Beam Therapeutics stock or one of its competitors? The main competitors of Beam Therapeutics include Grifols (GRFS), Telix Pharmaceuticals Limited American Depositary Shares (TLX), TG Therapeutics (TGTX), Nuvalent (NUVL), Legend Biotech (LEGN), Lantheus (LNTH), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Vaxcyte (PCVX), and Merus (MRUS). These companies are all part of the "pharmaceutical products" industry.
Beam Therapeutics vs. Its Competitors
Grifols (NASDAQ:GRFS) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.
Grifols pays an annual dividend of $0.36 per share and has a dividend yield of 4.0%. Beam Therapeutics pays an annual dividend of $0.90 per share and has a dividend yield of 5.0%. Grifols pays out 30.8% of its earnings in the form of a dividend. Beam Therapeutics pays out -19.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Beam Therapeutics is clearly the better dividend stock, given its higher yield and lower payout ratio.
In the previous week, Beam Therapeutics had 3 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Beam Therapeutics and 4 mentions for Grifols. Beam Therapeutics' average media sentiment score of 1.13 beat Grifols' score of 1.08 indicating that Beam Therapeutics is being referred to more favorably in the news media.
Beam Therapeutics has a consensus price target of $48.75, suggesting a potential upside of 172.50%. Given Beam Therapeutics' higher probable upside, analysts clearly believe Beam Therapeutics is more favorable than Grifols.
Grifols received 284 more outperform votes than Beam Therapeutics when rated by MarketBeat users. However, 59.13% of users gave Beam Therapeutics an outperform vote while only 56.23% of users gave Grifols an outperform vote.
99.7% of Beam Therapeutics shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 3.5% of Beam Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Grifols has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.
Grifols has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
Grifols has a net margin of 0.00% compared to Beam Therapeutics' net margin of -41.07%. Grifols' return on equity of 0.00% beat Beam Therapeutics' return on equity.
Summary
Beam Therapeutics beats Grifols on 12 of the 21 factors compared between the two stocks.
Get Beam Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BEAM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BEAM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Beam Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:BEAM) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy BEAM Stock Free BEAM Stock Alerts